1. Home
  2. HDL vs ANL Comparison

HDL vs ANL Comparison

Compare HDL & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HDL

SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares

HOLD

Current Price

$14.00

Market Cap

723.1M

ML Signal

HOLD

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$14.07

Market Cap

611.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
HDL
ANL
Founded
2016
2004
Country
Singapore
United States
Employees
N/A
N/A
Industry
Restaurants
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
723.1M
611.1M
IPO Year
2023
2022

Fundamental Metrics

Financial Performance
Metric
HDL
ANL
Price
$14.00
$14.07
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$20.00
AVG Volume (30 Days)
918.0
150.1K
Earning Date
05-20-2026
04-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$14.73
$36.02
Revenue Next Year
$12.94
N/A
P/E Ratio
$55.56
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.00
$0.88
52 Week High
$20.35
$17.25

Technical Indicators

Market Signals
Indicator
HDL
ANL
Relative Strength Index (RSI) 57.22 58.36
Support Level $13.07 $12.45
Resistance Level $15.40 $15.32
Average True Range (ATR) 0.12 0.95
MACD 0.12 -0.00
Stochastic Oscillator 83.33 60.26

Price Performance

Historical Comparison
HDL
ANL

About HDL SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares

Super Hi International Holding Ltd is an investment holding company, and its subsidiaries are principally engaged in restaurant operations, delivery business, and sales of hot pot condiment products and food ingredients located in the overseas market outside Mainland China, Hong Kong, Macau, and Taiwan. Its mission is to become a world-wide integrated restaurant group, build the world's Chinese cuisine brand, and promote Chinese culinary heritage world-wide.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

Share on Social Networks: